Cross-disciplinary research stirs new challenges into the study of the structure, function and systems biology of complement

Advances in Experimental Medicine and Biology

Volumn 586, Issue , 2006, Pages 1-16

  Mastellos, Dimitrios ^a   Lambris, John D ^b  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934435608     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-34134-X_1     Document Type: Conference Paper

References (66)

1. M.J. Walport, Complement. First of two parts, N Engl J Med 344(14), 1058-1066 (2001).
2. A. Sahu and J.D. Lambris, Structure and biology of complement protein C3, a connecting link between innate and acquired immunity, Immunol Rev 18035-48 (2001).
3. D. Mastellos and J.D. Lambris, Complement: more than a "guard" against invading pathogens? Trends Immunol 23(10), 485-491 (2002).
4. D. Mastellos, A.E. Germenis, and J.D. Lambris, Complement: an inflammatory pathway fulfilling multiple roles at the interface of innate immunity and development, Curr Drug Targets Inflamm Allergy 4(1), 125-127 (2005).
5. D. Morikis and J.D. Lambris, The electrostatic nature of C3d-complement receptor 2 association, J Immunol 172(12), 7537-7547 (2004).
6. L. Hood and D. Galas, The digital code of DNA, Nature 421(6921), 444-448 (2003).
7. D. Morikis and J.D. Lambris, Physical methods for structure, dynamics and binding in immunological research, Trends Immunol 25(12), 700-707 (2004).
8. B. Nagar, R.G. Jones, R.J. Diefenbach, D.E. Isenman and J.M. Rini, X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2, Science 280(5367), 1277-1281 (1998).
9. A.E. Prota, D.R. Sage, T. Stehle, and J.D. Fingeroth, The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding, Proc Natl Acad Sci USA 99(16), 10641-10646 (2002).
10. G. Szakonyi, J.M. Guthridge, D. Li, K. Young, V.M. Holers, and X.S. Chen, Structure of complement receptor 2 in complex with its C3d ligand, Science 292(5522), 1725-1728 (2001).
11. L. Clemenza and D.E. Isenman, Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21), J Immunol 165(7), 3839-3848 (2000).
12. A. Cooper and C.M. Johnson, Isothermal titration microcalorimetry, Methods Mol Biol 22137-150 (1994).
13. M.L. Doyle, Characterization of binding interactions by isothermal titration calorimetry, Curr Opin Biotechnol 8(1), 31-35 (1997).
14. M. Katragadda, D. Morikis and J.D. Lambris, Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin, J Biol Chem 279(53), 54987-54995 (2004).
15. D.L. Smith, Y.Z. Deng and Z.Q. Zhang, Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry, J Mass Spectrom 32(2), 135-146 (1997).
16. J.G. Mandell, A.M. Falick and E.A. Komives, Identification of protein-protein interfaces by decreased amide proton solvent accessibility, Proc Natl Acad Sci USA 95(25), 14705-14710 (1998).
17. J.G. Mandell, A.M. Falick and E.A. Komives, Measurement of amide hydrogen exchange by MALDI-TOF mass spectrometry, Anal Chem 70(19), 3987-3995 (1998).
18. M.S. Winters, D.S. Spellman and J.D. Lambris, Solvent accessibility of native and hydrolyzed human complement protein 3 analyzed by hydrogen/deuterium exchange and mass spectrometry, J Immunol 174(6), 3469-3474 (2005).
19. Sahu1 A and J.D. Lambris, Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics, Immunopharmacology 49(1-2), 133-148 (2000).
20. C.L. Harris, D.A. Fraser and B.P. Morgan, Tailoring anti-complement therapeutics, Biochem Soc Trans 30(Pt 6), 1019-1026 (2002).
21. A. Sahu, B.K. Kay and J.D. Lambris, Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library, J Immunol 157(2), 884-891 (1996).
22. A.M. Soulika, M.M. Khan, T. Hattori, F.W. Bowen, B.A. Richardson, C.E. Hack, A. Sahu, L.H. Edmunds, Jr. and J.D. Lambris, Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons, Clin Immunol 96(3), 212-221 (2000).
23. B. Nilsson, R. Larsson, J. Hong, G. Elgue, K.N. Ekdahl, A. Sahu and J.D. Lambris, Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation, Blood 92(5), 1661-1667 (1998).
24. A.E. Fiane, T.E. Mollnes, V. Videm, T. Hovig, K. Hogasen, O.J. Mellbye, L. Spruce, W.T. Moore, A. Sahu and J.D. Lambris, Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor compstatin, Transplant Proc 31(1-2), 934-935 (1999).
25. A.E. Fiane, T.E. Mollnes, V. Videm, T. Hovig, K. Hogasen, O.J. Mellbye, L. Spruce, W.T. Moore, A. Sahu and J.D. Lambris, Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts, Xenotransplantation 6(1), 52-65 (1999).
26. A.E. Fiane, V. Videm, J.D. Lambris, O.R. Geiran, J.L. Svennevig and T.E. Mollnes, Modulation of fluid-phase complement activation inhibits hyperacute rejection in a porcine-to-human xenograft model, Transplant Proc 32(5), 899-900 (2000).
27. T.E. Mollnes, O.L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K.T. Lappegard, J. Kohl and J.D. Lambris, Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation, Blood 100(5), 1869-1877 (2002).
28. A. Klegeris, E.A. Singh and P.L. McGeer, Effects of C-reactive protein and pentosan polysulphate on human complement activation, Immunology 106(3), 381-388 (2002).
29. S.T. Furlong, A.S. Dutta, M.M. Coath, J.J. Gormley, S.J. Hubbs, D. Lloyd, R.C. Mauger, A.M. Strimpler, M.A. Sylvester, C.W. Scott and P.D. Edwards, C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles, Immunopharmacology 48(2), 199-212 (2000).
30. A. Sahu, D. Morikis and J.D. Lambris, Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3, Mol Immunol 39(10), 557-566 (2003).
31. D. Morikis, N. Assa-Munt, A. Sahu and J.D. Lambris, Solution structure of compstatin, a potent complement inhibitor, Protein Sci 7, 619-627 (1998).
32. D. Morikis, A. Sahu, W.T. Moore and J.D. Lambris, Design, structure, function and application of compstatin in Bioactive peptides in drug discovery and design: medical aspects, 235-246 (1999).
33. A. Sahu, A.M. Soulika, D. Morikis, L. Spruce, W.T. Moore and J.D. Lambris, Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin, J Immunol 165(5), 2491-2499 (2000).
34. S.T. Furlong, A.S. Dutta, M.M. Coath, J.J. Gormley, S.J. Hubbs, D. Lloyd, R.C. Mauger, A.M. Strimpler, M.A. Sylvester, C.W. Scott and P.D. Edwards, C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles, Immunopharmacology 48(2), 199-212 (2000).
35. D. Morikis, M. Roy, A. Sahu, A. Troganis, P.A. Jennings, G.C. Tsokos and J.D. Lambris, The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR, J Biol Chem 277(17), 14942-14953 (2002).
36. A.M. Soulika, D. Morikis, M.R. Sarrias, M. Roy, L.A. Spruce, A. Sahu and J.D. Lambris, Studies of structure-activity relations of complement inhibitor compstatin, J Immunol 171(4), 1881-1890 (2003).
37. A. Sahu, B.K. Kay and J.D. Lambris, Inhibition of human complement by a C3-binding peptide isolated from a phage displayed random peptide library, J Immunol 157, 884-891 (1996).
38. A. Sahu, A.M. Soulika, D. Morikis, L. Spruce, W.T. Moore and J.D. Lambris, Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin, J Immunol 165(5), 2491-2499 (2000).
39. D. Morikis, M. Roy, A. Sahu, A. Troganis, P.A. Jennings, G.C. Tsokos and J.D. Lambris, The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR, J Biol Chem 277(17), 14942-14953 (2002).
40. A.M. Soulika, D. Morikis, M.R. Sarrias, M. Roy, L.A. Spruce, A. Sahu and J.D. Lambris, Studies of structure-activity relations of complement inhibitor compstatin, J Immunol 171(4), 1881-1890 (2003).
41. J.L. Klepeis, C.A. Floudas, D. Morikis, C.G. Tsokos, E. Argyropoulos, L. Spruce and J.D. Lambris, Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity, J Am Chem Soc 125(28), 8422-8423 (2003).
42. J.L. Klepeis, C.A. Floudas, D. Morikis and J.D. Lambris, Predicting peptide structures using NMR data and deterministic global optimization, J Comput Chem 20, 1354-1370 (1999).
43. Klepeis JL and C.A. Floudas, Ab initio tertiary structure prediction of proteins, J Global Optim 25(1), 113-140 (2003).
44. J.L. Klepeis, Schafroth H.D., Westerberg K.M. and C.A. Floudas, Deterministic global optimization and ab initio approaches for the structure prediction of polypeptides, dynamics of protein folding, and protein-protein interactions, Comput Methods Protein Folding Adv Chem Phys 120, 265-457 (2002).
45. B. Mallik, M. Katragadda, L.A. Spruce, C. Carafides, C.G. Tsokos, D. Morikis and J.D. Lambris, Design and NMR characterization of active analogues of compstatin containing non-natural aminoacids, J Med Chem 48(1), 274-286 (2005).
46. J. Mullick, A. Kadam and A. Sahu, Herpes and pox viral complement control proteins: "the mask of self", Trends Immunol 24(9), 500-507 (2003).
47. A. Sahu, S.N. Isaacs, A.M. Soulika and J.D. Lambris, Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway, J Immunol 160(11), 5596-5604 (1998).
48. A.M. Rosengard, Y. Liu, Z. Nie and R. Jimenez, Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement, Proc Natl Acad Sci USA 99(13), 8808-8813 (2002).
49. G. Sfyroera, M. Katragadda, D. Morikis, S.N. Isaacs and J.D. Lambris, Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins, J Immunol 174(4), 2143-2151 (2005).
50. T. Ideker, T. Galitski and L. Hood, A new approach to decoding life: systems biology, Annu Rev Genomics Hum Genet 2, 343-372 (2001).
51. R. Mack and M. Hehenberger, Text-based knowledge discovery: search and mining of life-sciences documents, Drug Discov Today 7(11 Suppl), S89-S98 (2002).
52. A. Persidis, S. Deftereos and A. Persidis, Systems literature analysis, Pharmacogenomics 5(7), 943-947 (2004).
53. D. Mastellos, C. Andronis, A. Persidis and J.D. Lambris, Novel biological networks modulated by complement, Clin Immunol 115(3), 225-235 (2005).
54. Y. Kimura, M. Madhavan, M.K. Call, W. Santiago, P.A. Tsonis, J.D. Lambris and K. Rio-Tsonis, Expression of complement 3 and complement 5 in newt limb and lens regeneration, J Immunol 170(5), 2331-2339 (2003).
55. C.W. Strey, M. Markiewski, D. Mastellos, R. Tudoran, L.A. Spruce, L.E. Greenbaum and J.D. Lambris, The proinflammatory mediators C3a and C5a are essential for liver regeneration, J Exp Med 198(6), 913-923 (2003).
56. R. Reca, D. Mastellos, M. Majka, L. Marquez, J. Ratajczak, S. Franchini, A. Glodek, M. Honczarenko, L.A. Spruce, A. Janowska-Wieczorek, J.D. Lambris and M.Z. Ratajczak, Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1, Blood 101(10), 3784-3793 (2003).
57. R. Taub, Liver regeneration: from myth to mechanism, Nat Rev Mol Cell Biol 5(10), 836-847 (2004).
58. D. Mastellos, J.C. Papadimitriou, S. Franchini, P.A. Tsonis and J.D. Lambris, A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration, J Immunol 166(4), 2479-2486 (2001).
59. M.M. Markiewski, D. Mastellos, R. Tudoran, R.A. Deangelis, C.W. Strey, S. Franchini, R.A. Wetsel, A. Erdei and J.D. Lambris, C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury, J Immunol 173(2), 747-754 (2004).
60. X. Sun, C.D. Funk, C. Deng, A. Sahu, J.D. Lambris and W.C. Song, Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting, Proc Natl Acad Sci USA 96(2), 628-633 (1999).
61. J. Ratajczak, R. Reca, M. Kucia, M. Majka, D.J. Allendorf, J.T. Baran, A. Janowska-Wieczorek, R.A. Wetsel, G.D. Ross and M.Z. Ratajczak, Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow, Blood 103(6), 2071-2078 (2004).
62. C.T. Esmon, Interactions between the innate immune and blood coagulation systems, Trends Immunol 25(10), 536-542 (2004).
63. I.J. Laudes, J.C. Chu, S. Sikranth, M. Huber-Lang, R.F. Guo, N. Riedemann, J.V. Sarma, A.H. Schmaier and P.A. Ward, Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis, Am J Pathol 160(5), 1867-1875 (2002).
64. R.F. Guo and P.A. Ward, Role of C5a in inflammatory responses, Annu Rev Immunol 23821-852 (2005).
65. K. Ikeda, K. Nagasawa, T. Horiuchi, T. Tsuru, H. Nishizaka and Y. Niho, C5a induces tissue factor activity on endothelial cells, Thromb Haemost 77(2), 394-398 (1997).
66. B.J.C. Janssen, E.G. Huizinga, H.C.A. Raaijmakers, A. Roos, M.R. Daha, K. Nilsson-Ekdahl, B. Nilsson and P. Gros, Structures of complement component C3 provide insights into the function and evolution of immunity, Nature 437, 505-511 (2005).